全球治療性血漿交換市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

預計到 2032 年，全球治療性血漿交換市場的市場規模將從 2023 年的 25.3 億美元達到近 51.7 億美元，2024-2032 年研究期間的CAGR為 8.26%。

治療性血漿置換 (TPE)，也稱為血漿置換術，是一種去除、處理、返回患者血漿的醫療程序。 TPE 的主要目標是透過選擇性去除血漿成分（例如抗體、免疫複合物和其他可能導致各種醫療狀況的物質）來改變患者血液的成分。該過程涉及一種稱為離心機的設備，該設備將血液分離成各種成分，從而有針對性地去除血漿。

市場動態

治療性血漿置換市場是由自體免疫疾病、神經系統疾病和神經肌肉疾病的日益普及所推動的。醫療技術的進步推動了這一成長，帶來了更有效率的 TPE 設備並改善了患者的治療效果。腎臟病治療腎臟疾病的應用不斷擴大，加上醫療保健專業人員和患者意識的不斷提高，都有助於市場的擴張。全球人口老化，對自體免疫疾病和神經系統疾病的易感性更高，刺激了對 TPE 干預措施的需求。醫療保健支出的增加、政府舉措以及醫療機構和研究組織之間的合作支持了 TPE 的可近性。臨床研究和治療指南以及患者對非侵入性治療的偏好在塑造市場方面發揮關鍵作用。此外，傳染病的全球影響強調了對多種治療方案的需求，進一步促進了治療性血漿交換市場的動態成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球治療性血漿置換市場的各個細分市場進行了包容性評估。治療性血漿交換行業的成長和趨勢為這項研究提供了整體方法。

市場區隔

治療性血漿交換市場報告的這一部分提供了國家和地區層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按疾病適應症

• 神經系統疾病（慢性資訊性多髓鞘性多發性神經病變、重症肌無力、多發性壞死、視神經脊髓炎、格林-巴利綜合症）
• 腎臟疾病（腎臟移植後排斥、抗腎絲球基底膜 (Gsm) 疾病、韋格納肉芽腫病）
• 血液學疾病（血栓性血小板減少性紫斑症、溶血性尿毒症症候群、冷膽菌素血症、多發性骨髓瘤、代謝障礙、純合子女性高膽固醇血症、爆發性 Wiburn 病）
• 其他

按最終用戶

• 醫院
• 專業中醫
• 門診手術中心

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的治療性血漿交換市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。治療性血漿交換市場的主要參與者包括旭化成公司、​​百特國際公司、泰爾茂公司、B. Braun SE、Fresenius Kabi AG、SB-Kawasumi Laboratories Inc.、Haemonetics Corporation、Cerus Corporation、Charles River Laboratories 、Medica SpA。該部分包含競爭格局的整體視圖，其中包括各種策略發展，例如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：治療性血漿交換 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 依疾病適應症進行的市場吸引力分析
  • 最終用戶的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球治療性血漿交易市場分析：按疾病適應症

• 按疾病適應症概述
• 歷史和預測數據
• 按疾病指徵分析
• 神經系統疾病（慢性資訊性多髓鞘性多發性神經病變、重症肌無力、多發性壞死、視神經脊髓炎、格林-巴利綜合症）
• 腎臟疾病（腎臟移植後排斥、抗腎絲球基底膜 (GSM) 疾病、韋格納肉芽腫病）
• 血液學疾病（血栓性血小板減少性紫斑症、溶血性尿毒症症候群、冷膽菌素血症、多發性骨髓瘤、代謝障礙、純合子女性高膽固醇血症、爆發性 Wiburn 疾病）
• 其他

第 6 章：全球治療性血漿交易市場分析：依最終用戶分類

• 最終用戶概述
• 歷史和預測數據
• 最終用戶分析
• 醫院
• 專業中醫
• 門診手術中心

第 7 章：全球治療性血漿交易市場分析：依地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 8 章：治療性血漿交換公司的競爭格局

• 治療性血漿交換市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 9 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Asahi Kasei Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Baxter International Inc
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Terumo Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• B. Braun SE
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Fresenius Kabi AG
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• SB-Kawasumi Laboratories Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Haemonetics Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Cerus Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Charles River Laboratories
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Medica SpA
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

The global demand for Therapeutic Plasma Exchange Market is presumed to reach the market size of nearly USD 5.17 BN by 2032 from USD 2.53 BN in 2023 with a CAGR of 8.26% under the study period 2024 - 2032.

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is a medical procedure that removes, treats, retreturnsatient's blood plasma. The primary objective of TPE is to modify the composition of the patient's blood by selectively removing plasma components, such as antibodies, immune complexes, and other substances that may contribute to various medical conditions. The procedure involves a device known as a centrifuge, which separates blood into its components, allowing the targeted removal of plasma.

MARKET DYNAMICS

The Therapeutic plasma exchange market is driven by the increasing prevalence of autoimmune disorders, neurological diseases, and neuromuscular conditions. The growth is propelled by advancements in medical technology, leading to more efficient TPE equipment and improved patient outcomes. Expanding applications in nephrology for treating kidney disorders, coupled with rising awareness among healthcare professionals and patients, contribute to the market's expansion. The aging global population, with a higher susceptibility to autoimmune and neurological disorders, fuels the demand for TPE interventions. Increased healthcare expenditure, government initiatives, and collaborations between healthcare institutions and research organizations support the accessibility of TPE. Clinical research and treatment guidelines play a pivotal role in shaping the market, along with patient preferences for non-invasive treatments. Additionally, the global impact of infectious diseases emphasizes the need for versatile treatment options, further contributing to the dynamic growth of the Therapeutic plasma exchange market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of therapeutic plasma exchange. The growth and trends of therapeutic plasma exchange industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the therapeutic plasma exchange market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Indication

• Neurological Disorders (Chronic Infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome)
• Renal Disorders (Post-Renal Transplant Rejection, Anti-Glomerular Basement Membrane (Gsm) Disease, Wegener'S Granulomatosis)
• Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn'S Disease)
• Others

By End-User

• Hospitals
• Specialty Chnics
• Ambulatory Surgice Centers

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Therapeutic Plasma Exchange market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Therapeutic Plasma Exchange market include Asahi Kasei Corporation, Baxter International Inc, Terumo Corporation, B. Braun SE, Fresenius Kabi AG, SB-Kawasumi Laboratories Inc., Haemonetics Corporation, Cerus Corporation, Charles River Laboratories, Medica S.p.A. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . THERAPEUTIC PLASMA EXCHANGE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Disease Indication
  • 3.7.2 Market Attractiveness Analysis By End-user
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET ANALYSIS BY DISEASE INDICATION

• 5.1 Overview by Disease Indication
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Disease Indication
• 5.4 Neurological Disorders (Chronic infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome) Historic and Forecast Sales by Regions
• 5.5 Renal Disorders (Post-renal Transplant Rejection, Anti-glomerular Basement Membrane (GSM) Disease, Wegener's Granulomatosis) Historic and Forecast Sales by Regions
• 5.6 Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn's Disease) Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET ANALYSIS BY END-USER

• 6.1 Overview by End-user
• 6.2 Historical and Forecast Data
• 6.3 Analysis by End-user
• 6.4 Hospitals Historic and Forecast Sales by Regions
• 6.5 Specialty Chnics Historic and Forecast Sales by Regions
• 6.6 Ambulatory Surgice Centers Historic and Forecast Sales by Regions

7 . GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE THERAPEUTIC PLASMA EXCHANGE COMPANIES

• 8.1. Therapeutic Plasma Exchange Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF THERAPEUTIC PLASMA EXCHANGE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Asahi Kasei Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Baxter International Inc
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Terumo Corporation
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. B. Braun SE
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Fresenius Kabi AG
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. SB-Kawasumi Laboratories Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Haemonetics Corporation
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Cerus Corporation
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Charles River Laboratories
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Medica S.p.A
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Disease Indication (USD MN)
• Neurological Disorders (Chronic infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome) Market Sales by Geography (USD MN)
• Renal Disorders (Post-renal Transplant Rejection, Anti-glomerular Basement Membrane (GSM) Disease, Wegener's Granulomatosis) Market Sales by Geography (USD MN)
• Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn's Disease) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by End-user (USD MN)
• Hospitals Market Sales by Geography (USD MN)
• Specialty Chnics Market Sales by Geography (USD MN)
• Ambulatory Surgice Centers Market Sales by Geography (USD MN)
• Global Therapeutic Plasma Exchange Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Therapeutic Plasma Exchange Report
• Market Research Process
• Market Research Methodology
• Global Therapeutic Plasma Exchange Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Disease Indication
• Market Attractiveness Analysis by End-user
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Disease Indication (USD MN)
• Neurological Disorders (Chronic infiommatory Domyelinating Polyneuropathy, Myasthenia Grav, Multiple Secrosis, Neuromyelitis Optica, Guillain-Barre Syndrome) Market Sales by Geography (USD MN)
• Renal Disorders (Post-renal Transplant Rejection, Anti-glomerular Basement Membrane (GSM) Disease, Wegener's Granulomatosis) Market Sales by Geography (USD MN)
• Hematology Disorders (Thrombotic Thrombocytopenic Purpura, Hemalytic Uremic Syndrome, Cryngichulinemia, Multiple Myeloma, Metabolic Disorders, Homozygous Femilial Hypercholesterolemie, Fulminent Wiburn's Disease) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by End-user (USD MN)
• Hospitals Market Sales by Geography (USD MN)
• Specialty Chnics Market Sales by Geography (USD MN)
• Ambulatory Surgice Centers Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.